Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures

References

• HesdorfferDCLogroscinoGBennEKKatriNCascinoGHauserWAEstimating risk for developing epilepsy: a population-based study in Rochester, MinnesotaNeurology201176232721205691
   PubMed Web of Science ®Google Scholar
• ZarrelliMMBeghiERoccaWAHauserWAIncidence of epileptic syndromes in Rochester, MinnesotaEpilepsia1999401708171410612333
   PubMed Web of Science ®Google Scholar
• ForsgrenLHauserWAOlafssonESanderJWASSillanpaaMTomsonTMortality of epilepsy in developed countries: a reviewEpilepsia200546Suppl 11182716393174
   PubMed Web of Science ®Google Scholar
• StrineTWKobauRChapmanDPThurmanDJPricePBalluzLSPsychological distress, comorbidities, and health behaviors among U S adults with seizures: results from the 2002 national health interview surveyEpilepsia2005461133113916026567
   PubMed Web of Science ®Google Scholar
• KwanPBrodieMJEarly identification of refractory epilepsyN Engl J Med200034231431910660394
   PubMed Web of Science ®Google Scholar
• MohanrajRBrodieMJOutcomes in newly diagnosed localization-related epilepsiesSeizure20051431832315876543
   PubMed Web of Science ®Google Scholar
• RundfeltCThe new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cellsEur J Pharmacol19973362432499384239
   PubMed Web of Science ®Google Scholar
• WickendenADYuWZouAJeglaTWagonerPKRetigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channelsMol Pharmacol20005859160010953053
   PubMed Web of Science ®Google Scholar
• MainMJCryanJEDupereJRCoxBClareJJBurbidgeSAModulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabineMol Pharmacol20005825326210908292
   PubMed Web of Science ®Google Scholar
• SchenzerAFriedrichTPuschMMolecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabineJ Neurosci2005255051506015901787
   PubMed Web of Science ®Google Scholar
• WuttkeTVSeebohmGBailSMaljevicSLercheHThe new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gateMol Pharmacol2005671009101715662042
   PubMed Web of Science ®Google Scholar
• LangeWGeissendorferJSchenzerARefinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channelsMol Pharmacol20097527228019015229
   PubMed Web of Science ®Google Scholar
• RundfeldtCNetzerRThe novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunitsNeurosci Lett2000282737610713399
   PubMed Web of Science ®Google Scholar
• TatulianLDelmasPAbogadieFCBrownDAActivation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabineJ Neurosci2001215535554511466425
   PubMed Web of Science ®Google Scholar
• RundfeldtCNetzerRInvestigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channelsArzneimittelforschung2000501063107011190770
   PubMed Web of Science ®Google Scholar
• van RijnCMWillems-van BreeESynergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complexEur J Pharmacol20034649510012620500
   PubMed Web of Science ®Google Scholar
• RostockAToberCRundfeldtCD-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizuresEpilepsy Res1996232112238739124
   PubMed Web of Science ®Google Scholar
• De SarroGDi PaolaEDConteGPasculliMPDe SarroAInfluence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 miceNaynyn Schmiedebergs Arch Pharmacol2001363330336
   PubMed Web of Science ®Google Scholar
• MazaratiAWuJShinDKwonYSSankarRAntiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic studyEpilepsia2008491777178618503560
   PubMed Web of Science ®Google Scholar
• BiervertCSchroederBCKubischCA potassium channel mutation in neonatal human epilepsyScience19982794034069430594
   PubMed Web of Science ®Google Scholar
• CharlierCSinghNARyanSGA pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy familyNat Genet19981853559425900
   PubMed Web of Science ®Google Scholar
• SinghNACharlierCStaufferDA novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newbornsNat Genet19981825299425895
   PubMed Web of Science ®Google Scholar
• PorterRJPartiotASachedoRNohriaCAlvesWMRandomized, multicenter, dose-ranging trial of retigabine for partial-onset seizuresNeurology2007681197120417420403
   PubMed Web of Science ®Google Scholar
• BrodieMJLercheHGil-NagelAEfficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsyNeurology2010751817182420944074
   PubMed Web of Science ®Google Scholar
• FrenchJAAbou-KhalilBWLeroyRFRandomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsyNeurology2011761555156321451152
   PubMed Web of Science ®Google Scholar
• StrengTChristophTAnderssonKEUrodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious ratsJ Urol20041722054205815540788
   PubMed Web of Science ®Google Scholar
• RodeFSvaloJSheykhzadeMRonnLCBFunctional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladderEur J Pharmacol201063812112720385123
   PubMed Web of Science ®Google Scholar
• McNeillyRJTorchinCDAndersonLWKapetanovicIMKupferbergHJStrongJMIn vitro glucuronidation of D-23129, a novel anticonvulsant, by human liver microsomes and liver slicesXenobiotica1997274314419179986
   PubMed Web of Science ®Google Scholar
• HempelRSchupkeHMcNeillyPJMetabolism of retigabine (D-23129), a novel anticonvulsantDrug Metab Dispos19992761362210220491
   PubMed Web of Science ®Google Scholar
• HillerANguyenNStrassburgCRetigabine N-glucuronidation and its potential role in enterohepatic circulationDrug Metab Dispos19992760561210220490
   PubMed Web of Science ®Google Scholar
• BorlakJGasparicALocherMSchupkeHHermannRN-glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler Najjar type IIMetabolism2006571172116713428
   PubMed Web of Science ®Google Scholar
• FerronGMPaulJFruncilloRMultiple-dose, linear, dose-proprotional, pharmacokinetics of retigabine in healthy volunteersJ Clin Pharmacol20024217518211831540
   PubMed Web of Science ®Google Scholar
• HermannRFerronGMErbKEffects of age and sex on the disposition of retigabineClin Pharmacol Ther200373617012545144
   PubMed Web of Science ®Google Scholar
• HermannRKnebelNGNiebchGRichardsLBorlakJLocherMPharmacokinetic interaction between retigabine and lamotrigine in healthy subjectsEur J Clin Pharmacol20035879580212698305
   PubMed Web of Science ®Google Scholar
• FerronGMPatatAParksVRolanPTroySMLack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjectsBr J Clin Pharmacol200356394512848774
   PubMed Web of Science ®Google Scholar
• BialerMJohannessenSILevyRHPeruccaETomsonTWhiteHSProgressreport on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)Epilepsy Res200983143
   Google Scholar
• ShillitoPMolenaarPCVincentAAcquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nervesAnn Neurol1995387147227486862
   PubMed Web of Science ®Google Scholar
• AugerRGDaubeJRGomezMRLambertEHHereditary form of sustained muscle activity of peripheral nerve origin causing generalized myokymia and muscle stiffnessAnn Neurol19841513216324651
   PubMed Web of Science ®Google Scholar
• DedekKKunathBKananuraCReunerUJentschTJSteinleinOKMyokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channelProc Natl Acad Sci U S A200198122721227711572947
   PubMed Web of Science ®Google Scholar
• WuttkeTVJurkat-RottKPaulusWGarnkarekMLehrman-HornFLercheHPeripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutationsNeurology2007692045205317872363
   PubMed Web of Science ®Google Scholar
• Blackburn-MunroGJensenBSThe anticonvulsant retigabine attenuates nociceptive behaviors in rat models of persistent and neuropathic painEur J Pharmacol200346010911612559370
   PubMed Web of Science ®Google Scholar
• MunroGErichsenHKMirzaNRPharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxietyNeuropharmacology20075360961817714743
   PubMed Web of Science ®Google Scholar
• DenckerDDiasRPedersenMLHusumHEffect of the new antiepileptic drug retigabine in a rodent model of maniaEpilepsy Behav200812495318086455
   PubMed Web of Science ®Google Scholar
• HansenHHAndreasenJTWeikopPMirzaMScheel-KrugerJMikkelsenJDThe neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidineEur J Pharmacol2007570778817628530
   PubMed Web of Science ®Google Scholar
• RichterASanderSERundfeltCAntidystonic effects of Kv7 (KCNQ) channel openers in the dtsz mutant, an animal model of primary paroxysmal dystoniaBr J Pharmacol200614974775317016514
   PubMed Web of Science ®Google Scholar
• KorsgaardMPHartzBPBrownWDAhringPKStrobaekDMirzaNRAnxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channelsJ Pharmacol Exp Ther200531428229215814569
   PubMed Web of Science ®Google Scholar